ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study

Platzbecker, U., Germing, U., Giagounidis, A., Goetze, K., Kiewe, P., Mayer, K., Ottmann, Oliver ORCID: https://orcid.org/0000-0001-9559-1330, Radsak, M. P., Wolff, T., Haase, D., Hankin, M., Wilson, D. M., Laadem, A., Sherman, M. L. and Attie, K. M. 2014. ACE-536 increases hemoglobin and reduces transfusion burden in patients with low or intermediate-1 risk Myelodysplastic Syndromes (MDS): preliminary results from a phase 2 study. Blood 124 (21) , 411.

Full text not available from this repository.

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Schools > Medicine
Subjects:	R Medicine > R Medicine (General)
Publisher:	American Society of Hematology
ISSN:	0006-4971
Last Modified:	02 Nov 2022 09:55
URI:	https://orca.cardiff.ac.uk/id/eprint/96796

Actions (repository staff only)

Edit Item